19 results on '"Ribalov, Rinat"'
Search Results
2. Healthcare utilization, costs, and epidemiology of Huntington’s disease in Israel
3. Defining Utility Values for Chorea Health States in Patients with Huntington’s Disease
4. Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting
5. The Risk of Depression in a Large Huntington Disease Population Compared With Controls: Analysis of the Enroll-HD Registry Data (P1-11.012)
6. Chorea Severity Change Over Time in Huntington Disease and by Huntington Disease Stage (P1-11.010)
7. Baseline Characteristics and Treatment Patterns of a Global Huntington Disease Population Stratified by Chorea Severity (P2-11.011)
8. Burden of migraine in Brazil: A cross‐sectional real‐world study
9. The Clinical and Economic Burden of Tardive Dyskinesia in Israel
10. Prescription Opioids in Patients With Migraine in Southern Israel: a Retrospective Database Analysis (P17-2.001)
11. Direct Health Care Costs of Patients Suffering With Migraine in Southern Israel: a Retrospective Database Analysis (P17-2.006)
12. Migraine Epidemiology in Southern Israel: A Retrospective Database Study (P17-2.004)
13. Defining utility values for patients with tardive dyskinesia
14. Serious infections and cardiovascular complications among patients with chronic lymphocytic lymphoma treated with first-line ibrutinib or bendamustine/rituximab.
15. Real-world incidence and costs of serious infections and cardiovascular complications among patients with indolent non-Hodgkin lymphoma treated with first-line ibrutinib or bendamustine/rituximab.
16. Defining Utility Values for Chorea Health States in Patients With Huntington’s Disease (4360)
17. Budgetary Impact of Bendamustine Ready-to-Dilute Products in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma to a United States Infusion Facility
18. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103–113
19. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103-113.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.